Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design

Chemistry and Biology

Volumn 13, Issue 2, 2006, Pages 201-211

  Kontopidis, George ^a   McInnes, Campbell ^a   Pandalaneni, Sravan R ^a,c   McNae, Iain ^b   Gibson, Darren ^a   Mezna, Mokdad ^a   Thomas, Mark ^a   Wood, Gavin ^a   Wang, Shudong ^a   Walkinshaw, Malcolm D ^a,b   Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; ENZYME INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; DRUG DESIGN; ENZYME INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 32844469559     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2005.11.011     Document Type: Article

References (44)

1. E.A. Sausville Complexities in the development of cyclin-dependent kinase inhibitor drugs Trends Mol. Med. 8 2002 S32 S37
2. S. Ortega, M. Malumbres, and M. Barbacid Cell cycle and cancer: the G1 restriction point and the G1/S transition Curr. Genomics 3 2002 245 263
3. O. Tetsu, and F. McCormick Proliferation of cancer cells despite CDK2 inhibition Cancer Cell 3 2003 233 245
4. J.E. Grim, and B.E. Clurman Cycling without CDK2? Trends Cell Biol. 13 2003 396 399
5. M.V. Blagosklonny Do cells need CDK2 and Bcr-Abl? Cell Death Differ. 11 2004 249 251
6. P.M. Fischer The use of CDK inhibitors in oncology: a pharmaceutical perspective Cell Cycle 3 2004 742 746
7. P. Kaldis The cdk-activating kinase (CAK): from yeast to mammals Cell. Mol. Life Sci. 55 1999 284 296
8. G. Napolitano, B. Majello, and L. Lania Role of cyclinT/Cdk9 complex in basal and regulated transcription (Review) Int. J. Oncol. 21 2002 171 177
9. T. Oelgeschlager Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control J. Cell. Physiol. 190 2002 160 169
10. E. Agbottah, C. de La Fuente, S. Nekhai, A. Barnett, A. Gianella-Borradori, A. Pumfery, and F. Kashanchi Antiviral activity of CYC202 in HIV-1-infected cells J. Biol. Chem. 280 2005 3029 3042
11. C. Koumenis, and A. Giaccia Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis Mol. Cell. Biol. 17 1997 7306 7316
12. M. Ljungman, and D.P. Lane Opinion: transcription - guarding the genome by sensing DNA damage Nat. Rev. Cancer 4 2004 727 737
13. A. Huwe, R. Mazitschek, and A. Giannis Small molecules as inhibitors of cyclin-dependent kinases Angew. Chem. Int. Ed. Engl. 42 2003 2122 2138
14. P.M. Fischer, J. Endicott, and L. Meijer Cyclin-dependent kinase inhibitors L. Meijer A. Jézéquel M. Roberge Progress in Cell Cycle Research, Volume 5 2003 Editions de la Station Biologique de Roscoff Roscoff, France 235 248
15. Y. Dai, and S. Grant Cyclin-dependent kinase inhibitors Curr. Opin. Pharmacol. 3 2003 362 370
16. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
17. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massague, and N.P. Pavletich Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 376 1995 313 320
18. R. Honda, E.D. Lowe, E. Dubinina, V. Skamnaki, A. Cook, N.R. Brown, and L.N. Johnson The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles EMBO J. 24 2005 452 463
19. M.C. Morris, C. Gondeau, J.A. Tainer, and G. Divita Kinetic mechanism of activation of the CDK2/cyclin A complex. Key role of the C-lobe of the Cdk J. Biol. Chem. 277 2002 23847 23853
20. L. Connell-Crowley, M.J. Solomon, N. Wei, and J.W. Harper Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vitro Mol. Biol. Cell 4 1993 79 92
21. N.R. Brown, M.E. Noble, A.M. Lawrie, M.C. Morris, P. Tunnah, G. Divita, L.N. Johnson, and J.A. Endicott Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity J. Biol. Chem. 274 1999 8746 8756
22. H.L. De Bondt, J. Rosenblatt, J. Jancarik, H.D. Jones, D.O. Morgan, and S.H. Kim Crystal structure of cyclin-dependent kinase 2 Nature 363 1993 595 602
23. F. Heitz, M.C. Morris, D. Fesquet, J.-C. Cavadore, M. Doree, and G. Divita Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism Biochemistry 36 1997 4995 5003
24. C.E. Arris, F.T. Boyle, A.H. Calvert, N.J. Curtin, J.A. Endicott, E.F. Garman, A.E. Gibson, B.T. Golding, S. Grant, and R.J. Griffin Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles J. Med. Chem. 43 2000 2797 2804
25. S.T. Davis, B.G. Benson, H.N. Bramson, D.E. Chapman, S.H. Dickerson, K.M. Dold, D.J. Eberwein, M. Edelstein, S.V. Frye, and R.T. Gampe Jr. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors Science 291 2001 134 137
26. T.G. Davies, P. Tunnah, L. Meijer, D. Marko, G. Eisenbrand, J.A. Endicott, and M.E. Noble Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate Structure 9 2001 389 397
27. S. Wang, C. Meades, G. Wood, A. Osnowski, S. Anderson, R. Yuill, M. Thomas, M. Mezna, W. Jackson, and C. Midgley 2-Anilino-4-(thiazol-5-yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity J. Med. Chem. 47 2004 1662 1675
28. S.Y. Wu, I. McNae, G. Kontopidis, S.J. McClue, C. McInnes, K.J. Stewart, S. Wang, D.I. Zheleva, H. Marriage, and D.P. Lane Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop Structure 11 2003 399 410
29. T.G. Davies, J. Bentley, C.E. Arris, F.T. Boyle, N.J. Curtin, J.A. Endicott, A.E. Gibson, B.T. Golding, R.J. Griffin, and I.R. Hardcastle Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor Nat. Struct. Biol. 9 2002 745 749
30. S. Wang, G. Wood, C. Meades, G. Griffiths, C. Midgley, I. McNae, C. McInnes, S. Anderson, W. Jackson, and M. Mezna Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors Bioorg. Med. Chem. Lett. 14 2004 4237 4240
31. M.K. Dreyer, D.R. Borcherding, D.A. Dumont, N.P. Peet, J.T. Tsay, P.S. Wright, A.J. Bitonti, J. Shen, and S.-H. Kim Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717 J. Med. Chem. 44 2001 524 530
32. T.G. Davies, D.J. Pratt, J.A. Endicott, L.N. Johnson, and M.E. Noble Structure-based design of cyclin-dependent kinase inhibitors Pharmacol. Ther. 93 2002 125 133
33. M.P. Thomas, C. McInnes, and P.M. Fischer Protein structures in virtual screening: a case study with CDK2 J. Med. Chem. 49 2006 92 104
34. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
35. G. Kontopidis, M.J.I. Andrews, C. McInnes, A. Cowan, H. Powers, L. Innes, A. Plater, G. Griffiths, D. Paterson, and D.I. Zheleva Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange Structure 11 2003 1537 1546
36. C. McInnes, M.J. Andrews, D.I. Zheleva, D.P. Lane, and P.M. Fischer Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit Curr. Med. Chem. Anti-Canc. Agents 3 2003 57 69
37. D.I. Zheleva, C. McInnes, A.L. Gavine, N.Z. Zhelev, P.M. Fischer, and D.P. Lane Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A J. Pept. Res. 60 2002 257 270
38. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326
39. J. Pflugrath The finer things in X-ray diffraction data collection Acta Crystallogr. D Biol. Crystallogr. 55 1999 1718 1725
40. Leslie, A.G.W. (1992). Recent changes to the MOSFLM package for processing film and image plate data. In Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography, Volume 26.
41. Evans, P.R. (1993). Data reduction. In Proceedings of CCP4 Study Weekend on Data Collection & Processing, pp. 114-122.
42. CCP4 (Collaborative Computational Project, Number 4) The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
43. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
44. V.S. Lamzin, and K.S. Wilson Automated refinement for protein crystallography Methods Enzymol. 277 1997 269 305